After reviewing the Vapotherm results, UBS believes the competitive threat to Fisher & Paykel is modest.
The company’s market position appears stable, although Vapotherm’s focus on emergency departments, where it has a better offering for undifferentiated respiratory distress, needs to be monitored.
NZ$12.60 target, Sell reiterated.
Sector: Health Care Equipment & Services.
Current Price is $14.27. Target price not assessed.
